01/08/20 KDx Diagnostics announces FDA Breakthrough Device designation for URO17™, Innovative urine

January 8, 20200

CAMPBELL, Calif., Jan. 8, 2020 /PRNewswire/ — KDx Diagnostics, Inc. (KDx), announced today that the Food and Drug Administration (FDA) has granted “Breakthrough Device” designation for its URO17™ Bladder Cancer Recurrence Test … Read More

Leave a Reply

Your email address will not be published. Required fields are marked *